anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We report a case of a middle-aged woman with a rapidly growing abdominal mass that was diagnosed as myxoid pleomorphic liposarcoma, a recently recognised, rare and aggressive subtype of liposarcoma. The tumour exhibits a combination of histological features from both myxoid liposarcoma and pleomorphic liposarcoma. Genetic analysis revealed mutations in TP53 and RB1, along with widespread loss of heterozygosity. However, no DDIT3 gene translocation or MDM2/CDK4 gene amplification was detected. These genetic characteristics can be used to distinguish this type of liposarcoma from others. Two unusual gene fusion/rearrangements, CREB5::TERT fusion and ETV1::LFNG rearrangement, were identified. The patient underwent complete removal of the tumour without the use of radiotherapy or chemotherapy. No recurrence was observed during the follow-up period of 18 months.
RATIONALE AND OBJECTIVES: To compare urethral stricture shear wave elastography (SWE) with normal areas and assess its association with other explanatory variables.
SUBJECTS AND METHODS: we recruited all men with urethral stricture disease referred to our center between December 2021 and July 2023. Patients underwent SWE and elasticity in the stricture area, and one and three centimeters distant from the stricture were measured. Gathered data were analyzed using Freidman and post hoc analysis, correlation methods, student t-tests, and one-way ANOVA.
RESULTS: 22 patients were recruited for our study. Spongiofibrosis was significantly higher in the stricture area relative to the one-centimeter-distant adjacent area (p < .0005), in the one-centimeter-distant compared to the three-centimeter-distant area (p = .002), and in the stricture area relative to the three-centimeter-distant area (p < .0005). There was no association between elasticity ratio and patient age or stricture location. Likewise, there was no difference in elasticity ratios between bulbar and pendulous strictures (p = 0.19) or among different etiologies of urethral strictures (p = 0.76).
CONCLUSION: There is a significant difference in elasticity between the urethral stricture area and other parts of the corpus spongiosum. Normal areas closer to strictures are stiffer. The elasticity ratio is unrelated to patient age or prior internal urethromies. Neither stricture locations nor distinct urethral stricture etiologies differed in elasticity ratios.
Improving the efficiency of antiseizure medication entering the brain is the key to reducing its peripheral toxicity. A combination of intranasal administration and nanomedicine presents a practical approach for treating epileptic seizures via bypassing the blood-brain barrier. In this study, phenytoin (PHT) loaded layered double hydroxide nanoparticles (BSA-LDHs-PHT) were fabricated via a coprecipitation - hydrothermal method for epileptic seizure control. In this study, we expound on the preparation method and characterization of BSA-LDHs-PHT. In-vitro drug release experiment shows both rapid and continuous drug release from BSA-LDHs-PHT, which is crucial for acute seizure control and chronic epilepsy therapy. In-vivo biodistribution assays after intranasal administration indicate excellent brain targeting ability of BSA-LDHs. Compared to BSA-Cyanine5.5, BSA-LDHs-Cyanine5.5 were associated with a higher brain/peripheral ratio across all tested time points. Following intranasal delivery with small doses of BSA-LDHs-PHT, the latency of seizures in the pentylenetetrazole-induced mouse models was effectively improved. Collectively, the present study successfully designed and applied BSA-LDHs-PHT as a promising strategy for treating epileptic seizures with an enhanced therapeutic effect.
All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given \[ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and \< 3 cm)) for subject inclusion\]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered.
The invention discloses blood pressure reduction sauce. The blood pressure reduction sauce is used by the inventor to prevent hyperlipemia and carry out diet therapy on patients, is a diet therapy dish prepared by properly mixing beans, fruits and vegetables, which do not contain fat, cholesterol and the like and Chinese medicinal herbs, and keeps and absorbs a manufacturing process of the chilli sauce of the Korean nationality and peculiar ethnic flavor. The sauce is the first listed into a diet therapy menu, and creates the pioneering theory of making and richening diet therapy products. The blood pressure reduction source develops a new way for diet therapy for preventing the hyperlipemia in China and solves the problems of difficulty in the prevention and treatment of the hyperlipemia and no foods for the patients with the hyperlipemia. According to the blood pressure reduction sauce, a medicinal blood pressure reduction approach is changed. The blood pressure reduction sauce has edibleness, therapeutic value and broad market prospect, and is higher in competitiveness in the society.
Disclosed is a composition for repelling pests (e.g. insects and birds) from an animal carcass. This pest repelling composition contains a repellant (e.g. pepper extract) in admixture with a fluid vehicle, such as a light cooking oil. The repellant is present in a sufficient concentration to repel a pest when it contacts the animal carcass to which the composition has been applied. The composition may also include salt to help preserve the animal. The composition is applied to the exterior of the carcass. Repeated applications may be performed. The invention also includes a process for making the pest repelling composition.
PURPOSE: A composition for alpha glucosidase activity inhibition is provided to fundamentally reduce the amount of low sugar group which is absorbed into human body. CONSTITUTION: A composition for alpha glucosidase activity inhibition contains Pediococcus sp. JNU 534 (the accession number KCCM-10869P) strain or culture material of the Pediococcus species JNU 534 (the accession number KCCM-10869P) strain. A health supplement contains the composition for the alpha glucosidase activity inhibition. The foods are manufactured into formulations of powder, granule, tablet, capsule or drink medicine A food addition contains the composition for the alpha glucosidase activity inhibition. A fermented milk product contains the composition for the alpha glucosidase activity inhibition. A composition for preventing and treating anti-hyperglycemic contains the composition for the alpha glucosidase activity inhibition as an active ingredient.
PURPOSE:To provide the title membrane structure giving high stability even if the osmotic pressure of dispersion is varied over a wide range, for application to ribosome, micelles, microemulsions etc., made up of a muramyldipeptide derivative and other two compounds. CONSTITUTION:The objective membrane structure made up of (A) a muramyldipeptide derivative of the formula (Q is 20-60C fatty acid residue; A is L-alanine residue, L-serine residue or glycine residue; iso Gln is iso- glutamine residue), (B) a phosphatidylglycerol and (C) cholesterol. The amount of the component B to be used is 1/20-20 times pts.wt. based on the component A, and, for the component C, 1/20-5 times pts.wt. It is the most preferable that the composition ratio for these three components be 1:1:1 in terms of weight ratio. The present membrane structure can be obtained by mixing the above three components followed by dissolution in an organic solvent such as chloroform, distilling the solvent off, adding a buffer solution such as a phosphoric acid buffer solution to the system and then stirring.
PURPOSE: To obtain an anhydrous manicure excellent in stability with time, luster and excellent to keratin of nail, containing a specific resin in a solvent for manicure free from nitrocellulose. CONSTITUTION: This non-nitrocellulose manicure contains a resin which contains a resin in a solvent for manicure. The resin comprises a motif (unit) formed by copolymerization of 20-70% of at least one hydroxyalkyl (meth)acrylate of formula I (R' is H or CH3 ; R is a 1-6C saturated hydrocarbon group) and 30-80% of at least one hydroxyalkyl (meth)acrylate of formula II (R1 =R'; R2 is a hydrocarbon group containing a 2-4C and one or two OH groups). The copolymer does not comprise 30% or more of the unit derived from the copolymerization. The resin has >=0.1Pa. s viscosity in 28% ethyl acetate solution at 25 deg.C. A packed material comprises two parts of the manicure and an alcohol or its mixture.
PROBLEM TO BE SOLVED: To obtain a new polypeptide or its partial peptide playing a fixed role in a pathological function in the brain, useful for treating Alzheimer's disease, etc., and diagnosing various cerebral nerve degenerative disease, etc. by making the polypeptide, etc. have a specific amino acid sequence. SOLUTION: This polypeptide or its partial peptide has an amino acid sequence of the formula or >=85% homology to the amino acid sequence of the formula and serine protease activity. A host transformed with a vector containing a DNA (fragment) encoding the polypeptide or its partial peptide is cultured or raised and the polypeptide or its partial peptide is collected to produce the polypeptide or its partial peptide. An antibody having reactivity with the polypeptide or its partial peptide is prepared and a pathologically active substance is screened by using the DNA (fragment).
Behçet disease (BD) is an autoimmune and autoinflammatory disease mainly affecting the Silk Road countries. The interindividual severity of BD depends on differences in the polymorphic profiles of the patients. One of the most prominent markers, HLA-B51 positivity, is also observed in 40-60% of patients with BD on the Silk Road. Inflammatory markers such as interleukin 10 (IL-10) and interleukin 23 receptor (IL-23R) are also widely associated with BD etiology. The polymorphisms on these genes may change the susceptibility to BD. In this case-control study, we assessed the associations of IL-10 rs3024498 and IL-23R rs10889677 single-nucleotide polymorphisms (SNPs) with BD susceptibility, if any. Two hundred eighty HLA-B51-positive patients with BD and 300 healthy controls were genotyped for these SNPs using RFLP-PCR. The chi-square test was used for genotyping. We found that IL-23R rs10889677 CC and IL-10 rs3024498 CT genotype frequencies were higher in the BD group than in the control group (p < 0.0001 and p = 0.0293, respectively). The recessive model (AA + CC vs. AC) and combined genotype (AC + CT) results were also statistically significant (p < 0.0001 and p = 0.0364, respectively). We conclude that IL-23R rs10889677 and IL-10 rs3024498 SNPs may be associated with the susceptibility to BD.
Heritable pulmonary arterial hypertension (PAH) can be triggered by at least 18 genes. The most frequently altered gene is the bone morphogenetic protein receptor 2 (BMPR2). Further genes from the same pathway are also well known PAH-causing genes. Genetic testing can aid to confirm differential diagnoses such as a pulmonary veno-occlusive disease. It also enables the testing of healthy family members. In addition to the PAH patient population particularly served by genetic testing, this article touches on the mode of inheritance and provides insights into the first treatments soon on the market that rebalance the BMPR2 signaling pathway.
BACKGROUND: Porcine pathogenic Escherichia coli (E. coli), the globally recognized important pathogen, causes significant economic loss in the field. Enterotoxigenic E. coli (ETEC) causes porcine neonatal and post-weaning diarrhea (PWD), frequently carrying F4 adhesin, F18 adhesin, Heat-Stable toxin (ST), and Heat-Labile toxin (LT). Shiga Toxin-Producing E. coli (STEC) produces F18 adhesin and Shiga toxin type 2e (stx2e), majorly leading to systemic endothelial cell damage and edema disease. In this study, hemolytic pathogenic hybrid STEC/ETEC strains carrying ST and LT genes of ETEC and the Stx2e gene of STEC isolated from pigs with PWD in Taiwan were identified. The pathogenicity of a Taiwan hybrid STEC/ETEC strain was evaluated by oral inoculation in post-weaning pigs.
RESULTS: Next generation sequencing and multilocus sequence typing of two hybrid Taiwan porcine STEC/ETEC isolates indicated that these two isolates were closely related to the ST88 porcine hybrid STEC/ETEC isolated from pigs with watery diarrhea. Furthermore, the two hybrid Taiwan porcine STEC/ETEC isolates also displayed combinations of multiple resistance genes encoding mechanisms for target modification and antibiotic inactivation. Animal experiments confirmed that the Taiwan hybrid STEC/ETEC could cause watery diarrhea in post-weaning pigs with no signs of edema disease and minimal histopathological lesions.
CONCLUSION: To the best of the authors' knowledge, the present study is the first study demonstrating intestinal pathogenicity of the hybrid STEC/ETEC in pigs. The result suggests that the hybrid STEC/ETEC should be considered as a new emerging pathogen and a new target for vaccine development.
Activation of the kallikrein-kinin system promotes vascular leakage, inflammation, and neurodegeneration in ischemic stroke. Inhibition of plasma kallikrein (PK) - a key component of the KKS - in the acute phase of ischemic stroke has been reported to reduce thrombosis, inflammation, and damage to the blood-brain barrier. However, the role of PK during the recovery phase after cerebral ischemia is unknown. To this end, we evaluated the effect of subacute PK inhibition starting from day 3 on the recovery process after transient middle artery occlusion (tMCAO). Our study demonstrated a protective effect of PK inhibition by reducing infarct volume and improving functional outcome at day 7 after tMCAO. In addition, we observed reduced thrombus formation in cerebral microvessels, fewer infiltrated immune cells, and an improvement in blood-brain barrier integrity. This protective effect was facilitated by promoting tight junction reintegration, reducing detrimental matrix metalloproteinases, and upregulating regenerative angiogenic markers. Our findings suggest that PK inhibition in the subacute phase might be a promising approach to accelerate the post-stroke recovery process.
On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
Although sleep is essential for (recovery of) health, it is adversely affected by hospitalization, due to disease discomfort, environmental noise, and care routines, causing reduced sleep and increased disturbances. This study evaluates factors affecting sleep quality and quantity in hospitalized children and compares inpatient sleep with sleep at home. Using an observational, prospective study design, we assessed sleep in hospitalized children aged 1-12 years, admitted to a tertiary center, and compared this with home 6-8 weeks after discharge. We measured total sleep time (TST), sleep onset latency (SOL), wake after sleep onset (WASO), sleep efficiency, awakenings, and subjective sleep quality, using actigraphy, sleep diaries, and PROMIS questionnaires. We explored an array of sleep-disturbing factors. Regression analyses identified key determinants affecting sleep patterns, while mixed linear models compared sleep in hospital to sleep at home. Out of 621 eligible patients, 467 were invited, and 272 (58%) consented to participate. Key determinants of sleep included pain, number of previous admissions, (underlying) chronic illness, and environment-, staff-, and disease-related factors. Parents reported lower perceived sleep quality in the hospital compared to at home, 97-min (SE 9) lower TST, 100-min (5) longer WASO, more difficulties with falling asleep, lower sleep satisfaction, and more awakenings. Actigraphy outcomes revealed shorter TST (20 min (6)), but better sleep efficiency and fewer awakenings in the hospital. Conclusion: Sleep in hospital was compromised in comparison to sleep at home, primarily due to disturbances related to treatment, environment, and staff. These findings underscore the necessity and potential of relative simple interventions to improve sleep quality and minimize sleep disturbances in hospitalized children.
In a first aspect, an interface is associated with a structure which, in use, is deployed in an interior body region of a patient. The structure includes an operative element coupled to a controller, which establishes an operating condition for the operative element to perform a diagnostic or therapeutic procedure in the interior body region. The interface generates a first display comprising an image of the structure at least partially while the operative element performs the procedure. The interface also generates a second display comprising one or more data fields reflecting the operating condition of the controller. The interface enables selection of the first display or the second display for viewing on a display screen. In a second aspect, an interface for association with an electrode structure deployed in contact with heart tissue generates a real image of the electrode structure acquired by an imaging device. The interface also generates an idealized image of the electrode structure based at least in part upon the real image. The interface displays either the real image, or the idealized image, or both on a display screen.
PURPOSE:A pack preparation that contains, as an esential ingredient, carbon dioxide, thus stimulating blood flows in skins by directly acting on skins and giving well moisture to skin without unpleasant irritation to the applied sites and enabling long-term application without anxiety of dermatitises. CONSTITUTION:The objective pack preparation contains carbon dioxideliberating substances selected from carbon dioxide gas or combinations of carbonates such as sodium bicarbonate with an acid such as citric acid. The stimulation of blood flows by carbon dioxide reruires the pH in the atmosphere where the carbon dioxide exists to be 4-7, preferably 6.0-6.7 for good effect. The concentration of carbon dioxide in the preparation is preferably more than 60ppm. The preparation can also be combined with a conventional pack preparation or used solely as a carbon dioxide pack preparation. For example, a conventional pack preparation is put in a pressure vessel and high-pressure carbon dioxide or a carbon dioxide sources such as a combination of a carbonate with an acid is introduced into the vessel, the vessel is tightly closed. When it is applied, the content is pressed out of the vessel to the place to be packed.
Clear cell renal cell carcinoma (ccRCC), the most common type of renal cell carcinoma (RCC), is not sensitive to traditional radiotherapy and chemotherapy. The polyphenolic compound Gallic acid (GA) can be naturally found in a variety of fruits, vegetables and plants. Autophagy, an intracellular catabolic process, regulates the lysosomal degradation of organelles and portions in cytoplasm. It was reported that autophagy and GA could affect the development of several cancers. Therefore, the aim of the present study was to evaluate the effects of GA on ccRCC development and clarify the role of autophagy in this process. In the present study, the effects of GA on the proliferation, migration and invasion of ccRCC cells were investigated in vitro by Cell Counting Kit‑8, colony formation, flow cytometry, wound healing and Transwell migration assays, respectively. Additionally, the effects of GA on ccRCC growth and metastasis were evaluated using hematoxylin‑eosin and immunohistochemical staining in vivo. Moreover, it was sought to explore the underlying molecular mechanisms using transmission electron microscopy, western blotting and reverse transcription‑quantitative PCR analyses. In the present study, it was revealed that GA had a more potent viability inhibitory effect on ccRCC cells (786‑O and ACHN) than the effect on normal renal tubular epithelial cell (HK‑2), which demonstrated that GA selectively inhibits the viability of cancer cells. Furthermore, it was identified that GA dose‑dependently inhibited the proliferation, migration and invasion of ccRCC cells in vitro and in vivo. It was demonstrated that GA promoted the release of autophagy markers, which played a role in regulating the PI3K/Akt/Atg16L1 signaling pathway. All the aforementioned data provided evidence for the great potential of GA in the treatment of ccRCC.
Major depressive disorder (MDD) is a severe disorder that causes enormous loss of quality of life, and among the factors underlying MDD is stress in maternal deprivation (MD). In addition, classic pharmacotherapy has presented severe adverse effects. Centella asiatica (C. asiatica) demonstrates a potential neuroprotective effect but has not yet been evaluated in MD models. This study aimed to evaluate the effect of C. asiatica extract and the active compound madecassic acid on possible depressive-like behavior, inflammation, and oxidative stress in the hippocampus and serum of young rats submitted to MD in the first days of life. Rats (after the first day of birth) were separated from the mother for 3 h a day for 10 days. When adults, these animals were divided into groups and submitted to treatment for 14 days. After subjecting the animals to protocols of locomotor activity in the open field and behavioral despair in the forced swimming test, researchers then euthanized the animals. The hippocampus and serum were collected and analyzed for the inflammatory cytokines and oxidative markers. The C. asiatica extract and active compound reversed or reduced depressive-like behaviors, inflammation in the hippocampus, and oxidative stress in serum and hippocampus. These results suggest that C. asiatica and madecassic acid have potential antidepressant action, at least partially, through anti-inflammatory and antioxidant profiles.
The present invention provides various novel oligonucleotide analogs having one or more properties that make the subject compounds superior to conventional oligonucleotides for use in procedures employing oligonucleotides. The compounds of the invention arc oligonucleotide analogs in which the furanose ring of a naturally occurring nucleic acid is replaced with an amino acid or a modified amino alcohol residue. Some embodiments of the novel compounds of the invention arc particularly useful for the antisense control of gene expression. The compounds of the invention may also be used as nucleic acid hybridization probes or as primers. Another aspect of the invention is to provide monomeric precursors of the oligonucleotide analogs of the invention. These monomeric precursors may be used to synthesize the subject polynucleotide analogs. Another aspect of the invention is to provide formulations of the subject polynucleotide analogs that arc designed for the treatment or prevention of disease conditions. Yet another aspect of the invention is to provide methods for treating or preventing diseases, particularly viral infections and cell growth disorders. The subject disease treatment methods comprise the step of administering an effective amount of the subject polynucleotide analogs for use as antisense inhibitors.